FDA Clears AI Platform for Heart Procedure Planning
Cardiology has been recognized for its significant role in healthcare, particularly with the increasing integration of artificial intelligence (AI). Recently, the U.S. Food and Drug Administration (FDA) cleared an AI platform developed by DASI Simulations for use in planning transcatheter aortic valve replacement (TAVR) and other heart procedures. This highlights cardiology's ongoing momentum as a leader in AI technology, second only to radiology in AI algorithm approvals.
Understanding DASI Dimensions
Developed by DASI Simulations, an Ohio-based healthcare company, the DASI Dimensions platform is designed to analyze CT scans to identify and measure cardiac structures. This AI solution assists healthcare teams in planning complex heart procedures more accurately and efficiently.
The platform's development is credited to Lakshmi Prasad Dasi, PhD, a bioengineer from Georgia Tech University and the company's founder and Chief Technology Officer. The cloud-based software is part of DASI's mission to enhance physician efficiency and clinical outcomes through AI.
Enhancing Patient Outcomes
Teri Sirset, founder and CEO of DASI Simulations, emphasized the platform's potential to improve healthcare delivery: "Our mission—to provide an AI-powered structural heart platform that allows physicians to be more efficient and use their expertise more effectively—is moving forward with great momentum."
In conjunction with Vinod Thourani, MD, a cardiovascular surgeon at Piedmont Healthcare, Sirset highlights that clinical studies have shown notable improvements in patient outcomes, reduced complications, and decreased costs through the utilization of DASI's technology.
Cardiology's Leadership in AI
The approval of DASI Dimensions reaffirms cardiology's leadership in the use of AI. This specialty ranks just behind radiology in the number of AI algorithms approved by the FDA. Other companies, such as Siemens Healthineers, Nanox.AI, and AISAP, have also received key clearances, indicating a strong trend towards AI integration in cardiology.
Moreover, the FDA has appointed Ami B. Bhatt, MD, a cardiologist and digital health specialist, as the first chair of its new Digital Health Advisory Committee. This appointment underscores the vital role cardiologists play in AI-related healthcare advancements, fostering ongoing discussions and innovations.
With AI technologies like DASI Dimensions gaining traction, the future of cardiology and healthcare AI appears promising, offering enhanced precision and improved patient care.
